 |
Shanlian Hu is Professor of Health Economics. Director of Training Center for Health Management and Director of Pharmacoeconomics Research and Evaluation Center at School of Public Health, Fudan University, Shanghai, China. At present, he is the Chair of ISPOR China Doctor Association Chapter. He is elected as Chair of 2008-2010 ISPOR Asia Consortium Executive Committee as well. He made great contributions to ISPOR as the ISPOR 2nd Asia-Pacific Conference Program Committee Co-Chair in Shanghai, China, in 2006, and is playing a role in the planning of the upcoming ISPOR 3rd AP conference as Short Course Committee Co-Chair. He helped to organize a delegation of 30 policy-makers’ from China, with Novo Nordisk Pharmaceutical Co., to attend ISPOR 12th Annual European Congress in Dublin, Ireland in 2007.
He graduated from School of Public Health, Shanghai First Medical College, and further pursued his Master Degree in Epidemiology in Shanghai Medical College, and MSc of Medical Microbiology in the London School of Tropical Medicine and Hygiene, London, UK. In 1980-1982, he was a WHO Fellow pursuing health service studies in UCLA, UC Berkeley, and at Harvard in 1986. He has been a member of several China’s Ministry of Health (MOH) Advisory Committees, such as Health Policy and Management, New Type Rural Cooperative Medical System and Urban Community Health Care. Recently, he is also appointed as Director of Shanghai Health Development Research Center, under the leadership of Shanghai Bureau of Health. He uses these platforms to conduct pharmacoeconomics and drug policy research in China. In his career, he was the Deputy Director of National Health Economic Institution in MOH and the Coordinator of China Network of Training and Research in Health Economics and Financing between 1991 and 2005. He received several national advanced science and technology awards in 1990s. Over the past decade, he was a consultant for the World Bank, UNICEF, UNDP and AUSAID in China and several Asian countries. In the recent years, he has been working in pharmacoeconomics education, compiling reference books, disseminating pharmacoeconomic & outcomes research (PE & OR) knowledge to the policy-makers, pharmacoeconomic analyses and disease management for several pharmaceutical companies, such as Merck International Foundation, Pfizer, Sanofi-Aventis, GSK, Janssen. He is interested in drug pricing and reimbursement, national essential drug policy and systematic reviews on health reform and development
Under the transition of demographic, epidemiologic and risk factors, disease pattern has been changed through out the world. The quality and safety of medical services and universal coverage of health care and health insurance become the priorities of government health reform agenda. The accessibility and affordability of health service are being ranked as the first priority by the policy-makers. On the one hand, they are dealing with innovation of medicines and health technology which is essential for improving health status of population. On the other hand, the value of money and its cost-effectiveness should be considered because of the budget constraint. When searching all themes at ISPOR meetings in North America, Europe and Asia-Pacific regions, evidence-based health care decision-making has dominated. The new discipline of PE & OR are the tools to solve these problems. I am pleased to see that ISPOR plays a great role in this field. Now promoting education and actively reaching out to decision-makers is one of ISPOR’s Vision 2010.
My professional experience is to disseminate PE & OR and health technology assessment knowledge in academic and education environment. Pharmacoeconomics and outcomes research have been placed in the education curriculum as a core or elective course in the medical colleges and universities. In the policy research study, I have many chances to work with policy-makers. I do think capacity building and leadership development are so important that can make big change in the excellence of ISPOR.
It is a great honor to be recommended by the Board of Directors Nominations Committee as a candidate to serve on the ISPOR Board of Directors. Actually, it is really a challenge for me. I believe I will help the Society succeed in the following areas: 1) Working closely with different stakeholders, including academia, policy-makers and pharmaceutical industry in annual ISPOR activities; 2) Searching opportunities and funding from government and industry side to conduct capacity building programs to develop pharmacoeconomics and outcomes research and health technology assessment; 3) Promoting PE & OR in the Asia-Pacific region during my term as a Chair of 2008-2010 Asia Consortium Executive Committee of ISPOR.
TOP |
